Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.83 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.70 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.70 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21083733 | 0.92 | AGTR1 (0.83) | ACHEAGTR1LTB4R2 | |
| SCHEMBL25000106 | 0.90 | AGTR1 (0.72) | ACHEAGTR1LTB4R2AGTR2 | |
| SCHEMBL21084009 | 0.90 | ACHE (0.80) | ACHEAGTR1LTB4R2AGTR2 | |
| SCHEMBL21083897 | 0.86 | AGTR1 (0.67) | ACHEAGTR1LTB4R2AGTR2 | |
| SCHEMBL684147 | 0.83 | AGTR1 (1.00) | ACHEAGTR1LTB4R2 | |
| SCHEMBL21083730 | 0.82 | ACHE (0.82) | ACHEAGTR1LTB4R2AGTR2 | |
| SCHEMBL21125631 | 0.82 | ACHE (0.56) | ACHEAGTR1LTB4R2AGTR2 | |
| SCHEMBL683871 | 0.82 | AGTR1 (1.00) | ACHEAGTR1LTB4R2 | |
| SCHEMBL13539778 | 0.81 | ACHE (0.66) | ACHEAGTR1LTB4R2AGTR2 | |
| SCHEMBL21083908 | 0.81 | AGTR1 (0.61) | ACHEAGTR1LTB4R2AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-11407733-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-09 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407733-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | ACHE 1038/4885AGTR1 7/4885LTB4R2 133/4885 |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | ACHE 1038/4885AGTR1 7/4885LTB4R2 133/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | ACHE 1038/4885AGTR1 7/4885LTB4R2 133/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | ACHE 1038/4885AGTR1 7/4885LTB4R2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.